000			01467cam a22003257a 4500
001			29788
003			MED
005			20250512124731.0
008			170807t20172017xx b 001 0 eng d
010			_a 2017302047
020			_a9780128094006 (hbk.)
020			_a0128094001 (hbk.)
035			_a(OCoLC)ocn959880103
040			_aYDX _beng _cYDX _dBDX _dOCLCQ _dBTCTA _dWSU _dOCLCF _dDLC
042			_alccopycat
050	0	0	_aRC271.P76 _bT75 2017
082	0	0	_a615.7/98 _223
100	1		_aTridente, G., _eauthor.
245	1	0	_aAdverse events and oncotargeted kinase inhibitors / _cGiuseppe Tridente.
260			_aLondon : _bAcademic Press, _c©2017.
300			_axix, 715 p. ; _c28 cm
504			_aIncludes bibliographical references and index.
505	0		_aIntroduction -- Kinases -- Kinase inhibitors -- Adverse events -- Imantinib -- Gefitinib -- Erlotinib -- Sorafenib -- Sunitinib -- Dasatinib -- Lapatinib -- Nilotinib -- Pazopanib -- Vandetanib -- Vemurafenib -- Crizotinib -- Ruxolitinib -- Axitinib -- Bosutinib -- Regorafenib -- Cabozantinib -- Ponatinib -- Dabrafenib -- Trametinib -- Afatinib -- Idelaisib -- Ibrutinib -- Overview -- Conclusion and perspectives.
650		0	_aProtein-tyrosine kinase _xInhibitors.
650		2	_aProtein-tyrosine kinase $x Inhibitors.
650		7	_aProtein-tyrosine kinase _xInhibitors. _2fast _0(OCoLC)fst01079707
906			_a7 _bcbc _ccopycat _d2 _encip _f20 _gy-gencatlg
942			_2lcc _cBK _n0
999			_c29788 _d29788